Comparative Analysis of the Net Clinical Benefit of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis of Randomised Controlled Trials
European Cardiology Review · 09.05.2025 · 20
DOI: 10.15420/ecr.2025.07 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 09.05.2025. Verfasst von Ton Duy Mai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Stroke Centre, Bach Mai Hospital Hanoi, Vietnam. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Direct oral anticoagulants (DOACs) are the standard treatment for stroke prevention in AF. However, high-quality head-to-head comparisons of DOACs are lacking. This study compared oral anticoagulants in patients with AF.
Methods
Data were retrieved from eligible randomised controlled trials (RCTs). Interventions were ranked using the surface under the cumulative ranking curve (SUCRA) and the frequentist random effects model was applied. Efficacy outcomes included stroke, systemic embolism, MI, and all-cause mortality; the safety outcome was major bleeding. A composite outcome of efficacy and net clinical benefit was also evaluated.
Results
From 23,152 records, 11 eligible RCTs were identified and included in the study. Rivaroxaban was superior to vitamin K antagonists (VKA) in net clinical benefit (RR 0.75; 95% CI [0.59–0.94]; p=0.0133), but there were no significant differences between other DOACs and VKA or among the DOACs themselves. Rivaroxaban reduced the risk of the composite outcome of efficacy compared with dabigatran (RR 0.85; 95% CI [0.75–0.98]; p=0.02) and edoxaban (RR 0.84; 95% CI [0.75–0.95]; p=0.0051), but not apixaban (RR 0.89; 95% CI [0.89–1.02]; p=0.087). All DOACs showed superiority over VKA in efficacy, without an increased risk of major bleeding. Based on the SUCRA, rivaroxaban showed a favourable risk–benefit profile compared with the other anticoagulants.
Conclusion
This study showed that DOACs are superior to VKA in efficacy without increasing major bleeding risk, with rivaroxaban demonstrating the most balanced risk–benefit profile. Well-designed RCTs are needed to validate these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stroke Centre, Bach Mai Hospital Hanoi, Vietnam.
- Faculty of Stroke and Cerebrovascular Disease, VNU University of Medicine and Pharmacy Hanoi, Vietnam.
- Department of Emergency and Critical Care Medicine, Hanoi Medical University Hanoi, Vietnam.
- Heart Institute Ho Chi Minh City, Vietnam.
- Department of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City Ho Chi Minh City, Vietnam.
- Cardiovascular Department, Cho Ray Hospital Ho Chi Minh City, Vietnam.
ORCID-Profile: Ton Duy Mai, Tri Huynh Quang Ho, Sy Van Hoang, Hoai Thi Thu Nguyen, Jeyaraj Pandian, Tan Van Nguyen, Khoa Tien Vu, Minh Cong Tran, Hung Manh Pham
Zitieren
APA
Duy Mai, T., Ho, T. H. Q., Hoang, S. V., Nguyen, H. T. T., Pandian, J., Nguyen, T. V., Vu, K. T., Tran, G. S., Dao, V. P., Tran, M. C., & Pham, H. M. (2025). Comparative Analysis of the Net Clinical Benefit of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis of Randomised Controlled Trials. European Cardiology Review, 20. https://doi.org/10.15420/ecr.2025.07
Vancouver
Duy Mai T, Ho THQ, Hoang SV, Nguyen HTT, Pandian J, Nguyen TV, et al. Comparative Analysis of the Net Clinical Benefit of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis of Randomised Controlled Trials. European Cardiology Review. 2025;20. doi:10.15420/ecr.2025.07
BibTeX
@article{DuyMai2025,
author = {Duy Mai, Ton and Ho, Tri Huynh Quang and Hoang, Sy Van and Nguyen, Hoai Thi Thu and Pandian, Jeyaraj and Nguyen, Tan Van and Vu, Khoa Tien and Tran, Giang Song and Dao, Viet Phuong and Tran, Minh Cong and Pham, Hung Manh},
title = {Comparative Analysis of the Net Clinical Benefit of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis of Randomised Controlled Trials},
journal = {European Cardiology Review},
year = {2025},
volume = {20},
doi = {10.15420/ecr.2025.07}
}
EUVIMED